Cargando…
A Clinical Framework for Assessing Cannabis-Related Impairment Risk
Clinicians play an important role in promoting safe and responsible medical cannabis use. One essential component to safe use is considering a patient's risk of neurocognitive impairment. However, there remains a lack of practical guidance on how clinicians can evaluate this risk for medical ca...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272752/ https://www.ncbi.nlm.nih.gov/pubmed/35832600 http://dx.doi.org/10.3389/fpsyt.2022.883517 |
_version_ | 1784744938238377984 |
---|---|
author | MacCallum, Caroline A. Lo, Lindsay A. Pistawka, Carly A. Christiansen, April Boivin, Michael Snider-Adler, Melissa |
author_facet | MacCallum, Caroline A. Lo, Lindsay A. Pistawka, Carly A. Christiansen, April Boivin, Michael Snider-Adler, Melissa |
author_sort | MacCallum, Caroline A. |
collection | PubMed |
description | Clinicians play an important role in promoting safe and responsible medical cannabis use. One essential component to safe use is considering a patient's risk of neurocognitive impairment. However, there remains a lack of practical guidance on how clinicians can evaluate this risk for medical cannabis patients. Here, a practical framework is presented for clinicians to assess and stratify cannabis-associated impairment risk. The proposed framework is intended to practically guide healthcare providers in gaining a more comprehensive review of a patient's impairment-related factors. This framework can be used to assess impairment risk for patients currently using or considering medical cannabis and is recommended for all patients who perform safety-sensitive duties. Healthcare providers (HCP) managing patient's medical cannabis or those conducting assessments to determine risk of impairment for safety-sensitive workplaces can utilize this framework to stratify patients' risk of impairment. Such assessments can inform patient-specific needs for support, education, and guidance, to ensure cannabis is used safely and responsibly. |
format | Online Article Text |
id | pubmed-9272752 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92727522022-07-12 A Clinical Framework for Assessing Cannabis-Related Impairment Risk MacCallum, Caroline A. Lo, Lindsay A. Pistawka, Carly A. Christiansen, April Boivin, Michael Snider-Adler, Melissa Front Psychiatry Psychiatry Clinicians play an important role in promoting safe and responsible medical cannabis use. One essential component to safe use is considering a patient's risk of neurocognitive impairment. However, there remains a lack of practical guidance on how clinicians can evaluate this risk for medical cannabis patients. Here, a practical framework is presented for clinicians to assess and stratify cannabis-associated impairment risk. The proposed framework is intended to practically guide healthcare providers in gaining a more comprehensive review of a patient's impairment-related factors. This framework can be used to assess impairment risk for patients currently using or considering medical cannabis and is recommended for all patients who perform safety-sensitive duties. Healthcare providers (HCP) managing patient's medical cannabis or those conducting assessments to determine risk of impairment for safety-sensitive workplaces can utilize this framework to stratify patients' risk of impairment. Such assessments can inform patient-specific needs for support, education, and guidance, to ensure cannabis is used safely and responsibly. Frontiers Media S.A. 2022-06-24 /pmc/articles/PMC9272752/ /pubmed/35832600 http://dx.doi.org/10.3389/fpsyt.2022.883517 Text en Copyright © 2022 MacCallum, Lo, Pistawka, Christiansen, Boivin and Snider-Adler. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Psychiatry MacCallum, Caroline A. Lo, Lindsay A. Pistawka, Carly A. Christiansen, April Boivin, Michael Snider-Adler, Melissa A Clinical Framework for Assessing Cannabis-Related Impairment Risk |
title | A Clinical Framework for Assessing Cannabis-Related Impairment Risk |
title_full | A Clinical Framework for Assessing Cannabis-Related Impairment Risk |
title_fullStr | A Clinical Framework for Assessing Cannabis-Related Impairment Risk |
title_full_unstemmed | A Clinical Framework for Assessing Cannabis-Related Impairment Risk |
title_short | A Clinical Framework for Assessing Cannabis-Related Impairment Risk |
title_sort | clinical framework for assessing cannabis-related impairment risk |
topic | Psychiatry |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272752/ https://www.ncbi.nlm.nih.gov/pubmed/35832600 http://dx.doi.org/10.3389/fpsyt.2022.883517 |
work_keys_str_mv | AT maccallumcarolinea aclinicalframeworkforassessingcannabisrelatedimpairmentrisk AT lolindsaya aclinicalframeworkforassessingcannabisrelatedimpairmentrisk AT pistawkacarlya aclinicalframeworkforassessingcannabisrelatedimpairmentrisk AT christiansenapril aclinicalframeworkforassessingcannabisrelatedimpairmentrisk AT boivinmichael aclinicalframeworkforassessingcannabisrelatedimpairmentrisk AT snideradlermelissa aclinicalframeworkforassessingcannabisrelatedimpairmentrisk AT maccallumcarolinea clinicalframeworkforassessingcannabisrelatedimpairmentrisk AT lolindsaya clinicalframeworkforassessingcannabisrelatedimpairmentrisk AT pistawkacarlya clinicalframeworkforassessingcannabisrelatedimpairmentrisk AT christiansenapril clinicalframeworkforassessingcannabisrelatedimpairmentrisk AT boivinmichael clinicalframeworkforassessingcannabisrelatedimpairmentrisk AT snideradlermelissa clinicalframeworkforassessingcannabisrelatedimpairmentrisk |